Guselkumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1062 publications

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews
Published: June 23, 2026

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

Journal: mAbs
Published: June 17, 2026

Combination Guselkumab and Secukinumab for Plaque Psoriasis.

Combination Guselkumab and Secukinumab for Plaque Psoriasis.

Journal: Cutis
Published: May 15, 2026

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 05, 2026

Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report.

Achieving Rapid Remission With Guselkumab in a Moderately Active Ulcerative Colitis Patient With High Infectious Risk and Inadequate Response to Advanced Therapy: A Case Report.

Journal: Cureus
Published: April 28, 2026

A Rapid and Marked Response to Guselkumab in Extensive Plaque Psoriasis: A Case Report.

A Rapid and Marked Response to Guselkumab in Extensive Plaque Psoriasis: A Case Report.

Journal: Cureus
Published: April 27, 2026

Granulomatous prostatitis masquerading as suspected prostate cancer in a young patient on immunotherapy for psoriasis.

Granulomatous prostatitis masquerading as suspected prostate cancer in a young patient on immunotherapy for psoriasis.

Journal: BMJ case reports
Published: April 24, 2026

Disproportionality analysis of drug-associated tinnitus safety signals: a 43-year pharmacovigilance study.

Disproportionality analysis of drug-associated tinnitus safety signals: a 43-year pharmacovigilance study.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 23, 2026

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.

Journal: Cureus
Published: April 21, 2026

New-Onset Vitiligo During Guselkumab Therapy for Psoriasis.

New-Onset Vitiligo During Guselkumab Therapy for Psoriasis.

Journal: American journal of therapeutics
Published: April 09, 2026

Interleukin-23 Inhibitors in Inflammatory Bowel Disease.

Interleukin-23 Inhibitors in Inflammatory Bowel Disease.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 08, 2026

Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine
Published: April 07, 2026
Showing 1-12 of 1,062

Last Updated: 06/30/2026